Utility Values From Individuals With Knee Osteoarthritis in the UK
Author(s)
Kristina S. Boye, MPH, MS, RPh, PhD1, Mathieu M. Janssen, PhD2, Magaly Perez-Nieves, PhD1, Oliver Rivero-Arias, MSc, DPhil2, Sylvia Gonsahn-Bollie, MD1, Juan Manuel Ramos-Goñi, BS, MSc, PhD2;
1Eli Lilly and Company, Indianapolis, IN, USA, 2Maths in Health, Klimmen, Netherlands
1Eli Lilly and Company, Indianapolis, IN, USA, 2Maths in Health, Klimmen, Netherlands
OBJECTIVES: Osteoarthritis is one of the most frequent causes of mobility dependence and disability due to the associated pain. Specifically, 5.4 million individuals in the UK are affected by knee osteoarthritis (KOA) resulting in a significant negative impact on health-related quality of life (HRQoL). The main objective of this study was to estimate utility values (UVs) using the common 0 (dead) - 1 (full health) quality-adjusted life years scale associated with different levels of pain from individuals with KOA.
METHODS: Six different health state vignettes were developed using best practices and real-world data from the Osteoarthritis Initiative (OAI) database that included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) instrument. Data from individuals with KOA included in OAI were classified into 6 categories of pain profiles using patient responses to the following WOMAC pain items: pain while walking; pain while climbing stairs; pain while sleeping; pain while resting and pain while standing; with each pain item having a response levels of 0 (no), 1 (slight), 2 (moderate), 3 (severe) and 4 (extreme). The six vignettes identified the most frequent response levels of pain items.
RESULTS: 198 interviews were conducted using a time-trade-off method in individuals with KOA in the UK. The participants’ mean age was 51.6 years and 58.6% were females. Mean UVs ranged from 0.983 for the mildest health state, which was described as slight pain while climbing stairs and no pain on the other items, to 0.305 for the most severe health state which was described as extreme pain in all items.
CONCLUSIONS: This is the first set of UVs estimated using vignettes describing different levels of pain commonly reported by individuals with KOA. The results demonstrate considerable HRQoL burden in individuals with KOA. This evidence may be useful in future cost-effectiveness models that evaluate KOA treatments.
METHODS: Six different health state vignettes were developed using best practices and real-world data from the Osteoarthritis Initiative (OAI) database that included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) instrument. Data from individuals with KOA included in OAI were classified into 6 categories of pain profiles using patient responses to the following WOMAC pain items: pain while walking; pain while climbing stairs; pain while sleeping; pain while resting and pain while standing; with each pain item having a response levels of 0 (no), 1 (slight), 2 (moderate), 3 (severe) and 4 (extreme). The six vignettes identified the most frequent response levels of pain items.
RESULTS: 198 interviews were conducted using a time-trade-off method in individuals with KOA in the UK. The participants’ mean age was 51.6 years and 58.6% were females. Mean UVs ranged from 0.983 for the mildest health state, which was described as slight pain while climbing stairs and no pain on the other items, to 0.305 for the most severe health state which was described as extreme pain in all items.
CONCLUSIONS: This is the first set of UVs estimated using vignettes describing different levels of pain commonly reported by individuals with KOA. The results demonstrate considerable HRQoL burden in individuals with KOA. This evidence may be useful in future cost-effectiveness models that evaluate KOA treatments.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR129
Topic
Patient-Centered Research
Topic Subcategory
Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)